ASPirin in Reducing Events in the Elderly (ASPREE)

The ASPREE project is a long-term multi-center, bi-national study of aspirin and health in older adults, with the purpose to discover ways to maintain health, quality of life and independence as we age.

This landmark research has two components:

1) ASPREE (ASPirin in Reducing Events in the Elderly), a randomised, blinded, placebo-controlled clinical trial of low-dose (100mg) aspirin in healthy older adults. The trial’s ground-breaking findings underpin revised international aspirin prescribing guidelines.

2) ASPREE-XT (ASPREE – eXTension) study, an ongoing, follow-up observational health study to investigate long-lasting effects of low-dose aspirin on disease, such as cancer. Additionally, it investigates a broad range of factors that contribute to the maintenance of physical and cognitive health in older adults.

Findings from the ASPREE project advance the care and wellbeing of aging adults around the world.

The ASPREE Project is funded by the United States and Australian governments and is led by the Berman Center in the U.S. and Monash University in Melbourne, Australia.

For more information, visit: www.aspree.org.